Manifestaciones cutáneas asociadas a la enfermedad por el nuevo coronavirus SARS-CoV-2

Redondo-Sendino, Áurea; Sánchez, Isabel Cristina González; Fernández, Beatriz de Victoria

doi:10.1016/j.medcli.2020.04.057

Cited by 2 publications

(1 citation statement)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical characterization of the study groups confirmed the association of the presence of a more significant number of comorbidities in individuals with a history of COVID-19, as previously reported [ 18 , 19 ]. Interestingly, we observed a higher prevalence of dermatitis in the groups with prior COVID-19, which can be explained by two causes: in the last year, cases of occupational dermatitis have increased due to the prolonged use of personal protective equipment (PPE) and chronic stress levels [ 20 ] or as a manifestation of a drug for the treatment of COVID-19 [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection

et al. 2021

View full text Add to dashboard Cite

The main expected result of a vaccine against viruses is the ability to produce neutralizing antibodies. Currently, several vaccines against SARS-CoV-2 are being applied to prevent mortal complications, being Pfizer-BioNTech (BNT162b2) one of the first to be authorized in the USA and Mexico (11 December 2020). This study evaluated the efficacy of this vaccine on antibody production with neutralizing capacity and its side effects in healthcare workers with and without prior SARS-CoV-2 infection and in a group of unvaccinated individuals with prior COVID-19. The main findings are the production of 100% neutralizing antibodies in both groups after the second dose, well-tolerated adverse effects, the possible presence of immunosenescence, and finally, we support that a single dose of this vaccine in individuals with prior COVID-19 would be sufficient to achieve an immunization comparable to people without prior COVID-19 with a complete vaccination program (2 doses).

show abstract